A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs

Current HIV/AIDS Reports

Volumn 9, Issue 4, 2012, Pages 287-312

  Binford, Meredith Camp ^a   Kahana, Shoshana Y ^c   Altice, Frederick L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Adherence .Persons who use drugs (PWUDs); Antiretroviral adherence interventions; Antiretroviral therapy; Behavioral aspects ofHIV management; Combination antiretroviral therapy (cART); HIV and drug use; HIV treatment outcomes; Intervention; Substance abuse; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; DIAMORPHINE; METHADONE; METHAMPHETAMINE; OPIATE;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COGNITIVE THERAPY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHADONE TREATMENT; MOTIVATIONAL INTERVIEW; PATIENT COMPLIANCE; PATIENT COUNSELING; PSYCHOEDUCATION; PSYCHOTHERAPY; REVIEW; SOCIAL SUPPORT; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CHECKLIST; DRUG USERS; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; VIRAL LOAD;

EID: 84872185678     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0134-8     Document Type: Review

References (91)

1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-29. (Pubitemid 34786200)
2. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376 (9740):532-9.
3. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage 3rd GR, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522-8. (Pubitemid 33144917)
4. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med. 1998;129(6):503-5. (Pubitemid 28428088)
5. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-andtreat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793-800.
6. Parienti JJ, Ragland K, Lucht F, de la Blanchardiere A, Dargere S, Yazdanpanah Y, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50 (8):1192-7.
7. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-tomoderate adherence levels. PLoS One. 2008;3(7):e2783.
8. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, et al. Predictors of virologic failure and resistance in HIVinfected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38(9):1311-6. (Pubitemid 38608576)
9. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30. (Pubitemid 30432540)
10. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23(9):1035-46.
11. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, Hogg RS, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49(3):266- 71.
12. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65-72. (Pubitemid 46806622)
13. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saude Publica. 2006;22(4):705-18.
14. Harrigan PR, Hogg RS, DongWW, Yip B,Wynhoven B,Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339-47. (Pubitemid 40139758)
15. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003;17 (3):361-70. (Pubitemid 36223261)
16. Centers for Disease Control and Prevention. HIV Surveillance Report. 2010; vol. 22. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published March 2012. Accessed 18 July 2012.
17. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375 (9719):1014-28.
18. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006;83(6):1151-7. (Pubitemid 46024892)
19. Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2007;45(1):85-92. (Pubitemid 46684447)
20. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376 (9738):59-79. This review examines the complex interplay of between medical and psychiatric co-morbidity and medical consequences of treatment among HIV-infected persons who use drugs.
21. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192(6):958-66. (Pubitemid 41266791)
22. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279 (24):1977-83. (Pubitemid 28298277)
23. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a metaanalysis. AIDS Behav. 2010;14(4):731-47. This is an excellent meta-analysis of adherence to ART among people who use drugs and shows that once prescribed, adherence levels are quite high.
24. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550-4.
25. Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, et al. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav. 2011;15(8):1-13.
26. Angelino AF. Impact of psychiatric disorders on the HIVepidemic. Top HIV Med. 2008;16(2):99-103.
27. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence- Based Recommendations From an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156 (11):817-33. This article provides a comprehensive overview by the International Association of Physicians in AIDS Care of evidencebased strategies and recommendations for addressing linkage and retention in care and adherence to antiretroviral therapy.
28. Charania MR, Marshall KJ, Lyles CM, Crepaz N, Kay LS, Koening LJ, et al. Efficacy criteria and findings from a systematic review of U.S.-based HIV medication adherence interventions, 1996-2009. Submitted.
29. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178-93. This article provides a systematic review of how alcohol and its related disorders negatively impact into and retention in HIV care and adherence to antiretroviral therapy.
30. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411-7. (Pubitemid 44737097)
31. Cunningham CO, Sohler NL, Cooperman NA, Berg KM, Litwin AH, Arnsten JH. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users. Subst Use Misuse. 2011;46(2-3):218-32.
32. Haug NA, Sorensen JL, Gruber VA, Lollo N, Roth G. HAART adherence strategies for methadone clients who are HIV-positive: a treatment manual for implementing contingency management and medication coaching. Behav Modif. 2006;30(6):752-81. (Pubitemid 44563380)
33. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21-22):948- 52.
34. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242-57. (Pubitemid 352009054)
35. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, Rourke SB, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006;3:CD001442.
36. Sandelowski M, Voils CI, Chang Y, Lee EJ. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care. 2009;21(8):953-66.
37. Uldall KK, Palmer NB, Whetten K, Mellins C. Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. AIDS Care. 2004;16 Suppl 1: S71-96. (Pubitemid 39627976)
38. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS. 2008;22(11):1247-56.
39. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
40. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6 (7):e1000100.
41. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-66. (Pubitemid 30182431)
42. Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIVantiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215-21.
43. Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. "We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22(11):1305-13.
44. Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict. 2001;10(1):69-78. (Pubitemid 32201734)
45. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000;14(2):151-5. (Pubitemid 30116440)
46. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010;87 (4):592-602.
47. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188-94. (Pubitemid 44119095)
48. Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49(9):1433-40.
49. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45 (6):770-8. (Pubitemid 47378892)
50. Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21(11):1473-7. (Pubitemid 46988008)
51. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113(2-3):192-9.
52. Maru DS, Bruce RD,WaltonM, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results froma randomized controlled trial. J Acquir Immune Defic Syndr. 2009;50(2):176-81.
53. Berg KM, Litwin AH, Li X, Heo M, Arnsten JH. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention. Clin Infect Dis. 2011;53 (9):936-43.
54. Cooperman NA, Heo M, Berg KM, Li X, Litwin AH, Nahvi S, et al. Impact of adherence counseling dose on antiretroviral adherence and HIV viral load among HIV-infected methadone maintained drug users. AIDS Care. 2012;24(7):828-35
55. Ma M, Brown BR, Coleman M, Kibler JL, Loewenthal H, Mitty JA. The feasibility of modified directly observed therapy for HIVseropositive African American substance users. AIDS Patient Care STDS. 2008;22(2):139-46. (Pubitemid 351252587)
56. Babudieri S, Aceti A, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284(2):179-80. (Pubitemid 30460857)
57. Mitty JA, Macalino GE, Bazerman LB, Loewenthal HG, Hogan JW, MacLeod CJ, et al. The use of communitybased modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr. 2005;39(5):545-50. (Pubitemid 41098468)
58. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read. 2002;12(7):305-7. 12-6.
59. Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38 Suppl 5:S402-8. (Pubitemid 38738538)
60. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42(11):1628-35.
61. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care. 1998;10(3):297-312. (Pubitemid 28297777)
62. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadoneclinic- based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21(8):564-74. (Pubitemid 350194958)
63. Petry NM, Weinstock J, Alessi SM, Lewis MW, Dieckhaus K. Group-based randomized trial of contingencies for health and abstinence in HIV patients. J Consult Clin Psychol. 2010;78 (1):89-97.
64. Rigsby MO, Rosen MI, Beauvais JE, Cramer JA, Rainey PM, O'Malley SS, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15(12):841-7. (Pubitemid 32011833)
65. Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, Cramer J, et al. Improved adherence with contingency management. AIDS Patient Care STDS. 2007;21(1):30-40.
66. Parsons JT, Golub SA, Rosof E, Holder C.Motivational interviewing and cognitive behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46(4):443-50. (Pubitemid 350098695)
67. Parsons JT, Rosof E, Punzalan JC, Di Maria L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDS. 2005;19(1):31-9. (Pubitemid 40170841)
68. Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, Heckman CJ, Ceperich SD, Hettema J, et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+crack cocaine users. Drug Alcohol Depend. 2011;116(1-3):177-87.
69. Samet JH, Horton NJ, Meli S, Dukes K, Tripps T, Sullivan L, et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther. 2005;10(1):83-93. (Pubitemid 40767634)
70. Williams AB, Fennie KP, Bova CA, Burgess JD, Danvers KA, Dieckhaus KD. Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial. J Acquir Immune Defic Syndr. 2006;42(3):314-21. (Pubitemid 44050009)
71. Wang H, Zhou J, Huang L, Li X, Fennie KP, Williams AB. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV infected heroin users in Hunan of China. J Clin Nurs. 2010;19(3-4):380-8.
72. Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, et al. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med. 2002;55(2):235-46. (Pubitemid 34621441)
73. Deering KN, Shannon K, Sinclair H, Parsad D, Gilbert E, Tyndall MW. Piloting a peer-driven intervention model to increase access and adherence to antiretroviral therapy and HIV care among streetentrenched HIV-positive women in Vancouver. AIDS Patient Care STDS. 2009;23(8):603-9.
74. Feaster DJ, Mitrani VB, Burns MJ, McCabe BE, Brincks AM, Rodriguez AE, et al. A randomized controlled trial of Structural Ecosystems Therapy for HIV medication adherence and substance abuse relapse prevention. Drug Alcohol Depend. 2010;111(3):227-34.
75. Purcell DW, Latka MH, Metsch LR, Latkin CA, Gomez CA, Mizuno Y, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46 Suppl 2:S35-47. (Pubitemid 350293779)
76. McPherson-Baker S,Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12 (4):399-404. (Pubitemid 30618184)
77. Bamberger JD, Unick J, Klein P, Fraser M, Chesney M, Katz MH. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90(5):699-701. (Pubitemid 30246370)
78. Powell-Cope GM, White J, Henkelman EJ, Turner BJ. Qualitative and quantitative assessments of HAART adherence of substanceabusing women. AIDS Care. 2003;15(2):239-49. (Pubitemid 36470008)
79. Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003;80(3):416-27. (Pubitemid 37486645)
80. Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152(11):704-11.
81. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioiddependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S22-32.
82. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006;43 Suppl 4:S184-90. (Pubitemid 44901886)
83. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reductionintervention for HIV-positive injection drug users. Health Psychol. 2003;22(2):223-8. (Pubitemid 36307570)
84. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. In Press.
85. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88(1):54-63. (Pubitemid 46400307)
86. Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167-79.
87. Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3(9):e352.
88. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S23-35. (Pubitemid 44885639)
89. Antela A, Casado JL, Gonzalez MJ, Perez P, Perez-Elias MJ, Montilla P, et al. Influence of a methadone maintenance programme on the improved outcome of a cohort on injecting drug users with advanced HIV disease. AIDS. 1997;11 (11):1405-6.85.
90. Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008;34(2):161-70. (Pubitemid 351302169)
91. Tinoco I, Giron-Gonzalez JA, Gonzalez-Gonzalez MT, de Campos ergara A, Rodriguez-Felix L, Serrano A, et al. Efficacy of directly observed treatment of HIV infection: experience in AIDS welfare homes. Eur J Clin Microbiol Infect Dis. 2004;23(4):331-5. (Pubitemid 38678640)